Lloyd J. Old/Virginia and Daniel K. Ludwig Chair in Clinical Investigation; Chief, Melanoma & Immunotherapeutics Service; Associate Director, Ludwig Center for Cancer Immunotherapy
I am a medical oncologist who specializes in caring for people with melanoma. As a researcher, I am working to develop innovative ways to use the immune system to treat cancer. I have been at the forefront of cancer immunotherapy as a clinician-scientist and as a principal investigator of several pivotal clinical trials.
One of these was a large phase III trial that led to the FDA approval of ipilimumab (Yervoy®), an antibody now used as a first-line treatment for people with advanced melanoma. Ipilimumab was the first drug ever shown to improve survival in these patients. It has fundamentally changed this disease’s outcome — people who were once given a matter of months are living years longer in some cases. A number of patients I treated with ipilimumab in 2004 are still alive and free of cancer today. As a physician, nothing is more gratifying than being able to give someone his or her life back after cancer.
Despite the successes of ipilimumab, only about 20 percent of melanoma patients respond to the drug. This experience led me to test ipilimumab in combination with another immune drug, called nivolumab. I designed and led the phase I, II, and III clinical trials that led to the FDA approval of this combination in 2015 for advanced melanoma. You can hear about one patient’s experience with this combination here.
In 2011, I established the Immunotherapeutics Clinical Core, a specialized phase I outpatient unit at MSK that conducts novel immunotherapy trials, with a specific emphasis on identifying molecular biomarkers that can predict response. This group treats patients with a variety of cancers and has become a model for similar efforts by other major cancer centers throughout the world.
I received my undergraduate degree from Princeton University and my MD and PhD degrees from New York University, where I also fulfilled my residency program. After completing my fellowship at MSK, I remained on the faculty as part of the Melanoma and Immunotherapeutics Service. I am also a professor of medicine at Weill Cornell Medical College.
- Clinical Expertise: Melanoma; Immunotherapy and Cancer Vaccines
- Awards and Honors: The Solomon A. Berson Medical Alumni Achievement Award in Clinical and Translational Science from the NYU School of Medicine, 2016; New York Magazine Top Doctors (2013-2016); Board of Directors, American Society for Clinical Oncology (ASCO), 2015; Dr. Melvin L. and Dr. Sylvia F. Griem Lectureship & Award Recipient (Univ of Chicago), 2015; AICF Prize for Scientific Excellence in Medicine Award, 2014; Giant of Cancer Care in Melanoma Award, 2014; American Association for Cancer Research Richard and Hinda Rosenthal Memorial Award; Giants of Cancer Care in Melanoma Award, 2014; Virginia and Daniel K. Ludwig Chair for Clinical Investigation, 2013; Melanoma International Foundation's Doctor of the Year award, 2012; Director, Cancer Vaccine Collaborative, 2011; Melanoma Research Foundation – Humanitarian Award; 2010; Damon Runyon-Lilly Clinical Investigator Award, 2008
- Languages Spoken: English
- Education: MD, New York University School of Medicine; PhD, New York University Graduate School of Arts & Sciences
- Residencies: NYU Medical Center/Bellevue Hospital
- Fellowships: Memorial Sloan Kettering Cancer Center
- Board Certifications: Internal Medicine, Medical Oncology
Research is integral to our mission at Memorial Sloan Kettering, and clinical trials help us discover better forms of patient care and treatment. For you, this could mean access to a new therapy or therapy combination. Click to see a list of the trials I’m currently leading.
Clinical Trials Led by Jedd D. Wolchok
Clinical Trials Co-Investigated by Jedd D. Wolchok
- A Phase I Study Assessing the Immunomodulatory Activity of LY2157299 in Patients with Advanced Solid Tumors
- A Phase I Study of Immunotherapy with BMS-986016 Alone and with Nivolumab in Patients with Advanced Solid Tumors
- A Phase I Study of Ipilimumab and Nivolumab Immunotherapy plus Radiation Therapy for Metastatic Melanoma
- A Phase I Study of Lirilumab plus Nivolumab Immunotherapy in Patients with Advanced Solid Tumors
- A Phase I Study of Mogamulizumab with Tremelimumab or MEDI4736 in Patients with Advanced Cancers
- A Phase I Study of MOXR0916 in Patients with Advanced Cancers
- A Phase I Study of PF-05082566 Alone in Patients with Advanced Cancer, and in Combination with Rituximab in Patients with Non-Hodgkin Lymphoma
- A Phase I Study of Varlilumab plus Nivolumab Immunotherapy in Patients with Advanced Solid Tumors
- A Phase I/II Study of Immunotherapy with JTX-2011 Alone or with Nivolumab in Patients with Advanced Solid Tumors
- A Phase I/II Study of Immunotherapy with Nivolumab Alone and with Ipilimumab in Patients with Advanced or Metastatic Solid Tumors
- A Phase I/II Study of INCAGN01876 Immunotherapy in Patients with Advanced Solid Tumors
- A Phase I/II Study of Urelumab with Nivolumab Immunotherapy to Treat Advanced Solid Tumors and B-Cell Non-Hodgkin Lymphoma
- A Phase IB Study of Atezolizumab Immunotherapy plus Cobimetinib in Patients with Locally Advanced or Metastatic Solid Tumors
- A Phase Ib Study of RO5509554 (Emactuzumab) and MPDL3280A (Atezolizumab) Immunotherapy Given Together in Patients with Advanced Solid Tumors
- A Phase Ib/II Study of IMCgp100 with Durvalumab and/or Tremelimumab in Cutaneous Melanoma
- A Phase II Study Assessing Mediators of Response to Nivolumab and Ipilimumab Immunotherapy in Patients with Advanced Melanoma or Bladder Cancer
- A Phase II Study of Immunotherapy with Ipilimumab plus Nivolumab for Patients with Melanoma that Has Spread to the Brain
Most major health insurers offer plans that include MSK as one of their in-network providers. If MSK is in-network, it means all our doctors are too. Medicaid and New York State Medicare also provide benefits for care at MSK.Learn more